Answers are grounded in this paper and cite their sources.
The dawning era of novel recombinant factor VIII and factor IX concentrates, many of which have been bioengineered to achieve prolonged activity, brings with it the need to consider the most appropriate clinical laboratory approaches for potency assignment, as well as the measurement of postinfusion levels. This session will highlight the known limitations and inconsistencies between existing assay methodologies with respect to currently available products, and discuss some of the early data with respect to the novel agents.
No takes yet. Share an insight, caveat, or question.
Kitchen et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: